Navigation path

Pharmaceuticals - Community Register


Community list of not active orphan medicinal products


Product information

Imatinib mesilate

EU orphan designation number: EU/3/05/320
Active ingredient: Imatinib mesilate
Indication: Treatment of chronic eosinophilic leukaemia and the hypereosinophilic syndrome
Sponsor: Novartis Europharm Limited
Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Glivec on 27/08/2001 with the number EU/1/01/198

   Public summary of scientific opinion     EPAR

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
07/11/2005 Orphan designation EMEA/OD/040/05 (2005)4360 of 28/10/2005
16/04/2012 Removal of orphan designation from Community Register